Development Stage: Research-Grade Metabolic Assay Development
Short Description
Quantifies acetylcholine, a primary neurotransmitter.
Brand
OXPHOSight
Development Stage
Research-Grade Metabolic Assay Development
Description
Designed for neurobiology research, the OXPHOSight™ Acetylcholine Assay Kit is indispensable for validating neuroactive compounds that modulate cholinergic signaling pathways. This assay provides the sensitivity needed to investigate neurotransmitter dynamics in Alzheimer's disease models and neuromuscular disorder studies. By facilitating the screening of acetylcholinesterase inhibitors and receptor agonists, it accelerates the development of targeted neurological therapies.
Features
One-step procedure ensures reproducibility in neurological drug screening; Sensitive detection supports investigation of cholinergic pathway modulators.
Process Relevance
Neurotoxicity Screening
Application Stage
Pre-clinical Safety
Applications
Neurobiology research for studying cholinergic signaling and neuromuscular function.
Qualified With
Internal performance validation using reference standards under defined assay conditions.
Detection Method
Absorbance at 570 nm, or Fluorescence Detection (Ex 530 nm / Em 585 nm)
Store at −20 °C upon receipt to maintain reagent stability. Follow recommended handling procedures to ensure consistent assay performance.
Storage Comment
Avoid repeated freeze-thaw cycles. During use, minimize the time components are exposed to room temperature and return them promptly to −20 °C storage after handling. Do not store at elevated temperatures for extended periods.
Expiry Date
6 months under recommended storage conditions to ensure optimal performance.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Shipped on ice under temperature-controlled conditions.
Background
Acetylcholine is a primary neurotransmitter at neuromuscular junctions and in the parasympathetic nervous system. It regulates muscle contraction and cognitive functions; its degradation by acetylcholinesterase is a key target in Alzheimer's disease therapy.